Becton Dickinson & Co Stock Price, News & Analysis

BD (Becton, Dickinson and Company) has announced the shipment of its first over-the-counter (OTC) COVID-19 rapid antigen test, utilizing smartphone computer vision technology for result interpretation. Available for $39.99 with promotional pricing at $26.50 on Amazon, the BD Veritor™ test offers digital results in 15 minutes, simplifying at-home testing. It features automated reporting to health agencies and is suitable for individuals aged 14 and older. Authorized under Emergency Use Authorization, the test addresses common at-home testing challenges, including result interpretation and reporting.

BD (Becton, Dickinson and Company) announced the appointment of Dr. Carrie L. Byington to its board of directors, increasing the board to 13 members. Byington is the executive vice president and head of University of California Health, leading a $20 billion academic health system. Her experience includes significant roles at Texas A&M University and the University of Utah. The company views her appointment as timely, aligning with its BD 2025 strategy aimed at innovating in connected care and improving chronic disease outcomes.

On October 18, 2021, BD (Becton, Dickinson and Company) announced its new ESG strategy, Together We Advance, aimed at enhancing its commitment to health, community, and environmental stewardship. This strategy focuses on four pillars: Company Health, Planet Health, Community Health, and Human Health. BD set ambitious 2030 goals, including a 46% reduction in Scope 1 and 2 greenhouse gas emissions and carbon neutrality in direct operations by 2040. The strategy emphasizes climate change, responsible supply chains, and transparency, while aligning with the UN Sustainable Development Goals.

BD (Becton, Dickinson and Company) announced enhanced manufacturing capacity for injection devices to support U.S. vaccination efforts. Completed with the Department of Health and Human Services (HHS), the new lines bolster domestic supply amid ongoing COVID-19 challenges. This follows a $42 million investment from HHS in a previous capital project aimed at expanding BD's operations in Nebraska, underscoring a commitment to both current and future pandemic needs. BD has supplied hundreds of millions of devices, ensuring continuity in healthcare delivery as the flu season approaches.

BD (Becton, Dickinson and Company) has received 510(k) clearance from the FDA for the Rotarex™ Atherectomy System, expanding its indications to include treatment in peripheral arteries with stents, stent grafts, and bypasses. This device can now assist in the treatment of in-stent restenosis, a complication often arising in patients with peripheral arterial disease (PAD). With over a decade of clinical use, the Rotarex™ System is recognized for its efficacy in effectively managing arterial lesions and improving patient outcomes.

BD (Becton, Dickinson and Company) will report its fiscal 2021 fourth quarter and full year financial results on Nov. 4, 2021. A press release will be issued at approximately 6 a.m. ET, followed by a conference call and webcast at 8 a.m. ET to discuss the results and company strategy. Investors can access the webcast on BD's investor relations website. BD is a leading global medical technology company committed to improving healthcare through innovative technologies.

BD (Becton, Dickinson and Company) has joined the Race to Zero and the Business Ambition for 1.5°C, pledging to achieve net-zero emissions by 2050. This initiative aims to combat climate change, with commitments to reduce Scope 1 and 2 GHG emissions by 46% by 2030 and to be carbon neutral by 2040. The announcement will be celebrated on September 25, 2021, at the Global Citizen LIVE.

BD (Becton, Dickinson and Company) has been selected by Washington state to provide its BD Veritor™ Plus rapid antigen test for COVID-19 in K-12 schools. This easy-to-use test delivers results in just 15 minutes and will be available at no cost through a partnership with the Washington Department of Health. Schools can opt for a full-service testing program managed by Premier Medical Group, which will oversee testing protocols and result reporting. This service aims to keep schools open and safe while containing COVID-19 spread. The BD Veritor™ Plus system is authorized for emergency use, pending FDA clearance.

Vicarious Surgical and D8 Holdings Corp. have secured an additional $27 million in commitments for a private placement, raising total PIPE commitments to $142 million. The anticipated gross proceeds from their business combination amount to approximately $487 million, ensuring D8 meets the closing condition of having at least $125 million in available cash. Investors include Becton, Dickinson and Company (BD), major hospital groups, and notable figures like Bill Gates. Vicarious Surgical aims to enhance surgical outcomes using advanced robotics technology.